Shareholder Class Action

PHOENIX - Insys Therapeutics boosted its stock price with false and misleading statements about its "unethical off-label marketing," and the share price fell from $45.28 to $37.55 in a day when the truth came out, then fell another $9.88, shareholders claim in Federal Court.